PMID- 16731944
OWN - NLM
STAT- MEDLINE
DCOM- 20060816
LR  - 20240314
IS  - 0022-538X (Print)
IS  - 1098-5514 (Electronic)
IS  - 0022-538X (Linking)
VI  - 80
IP  - 12
DP  - 2006 Jun
TI  - Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 
      infection in native Africans.
PG  - 6056-60
AB  - Human leukocyte antigen (HLA) class I alleles can be grouped into supertypes 
      according to their shared peptide binding properties. We examined alleles of the 
      HLA-B58 supertype (B58s) in treatment-naive human immunodeficiency virus type 1 
      (HIV-1)-seropositive Africans (423 Zambians and 202 Rwandans). HLA-B and HLA-C 
      alleles were resolved to four digits by a combination of molecular methods, and 
      their respective associations with outcomes of HIV-1 infection were analyzed by 
      statistical procedures appropriate for continuous or categorical data. The 
      effects of the individual alleles on natural HIV-1 infection were heterogeneous. 
      In HIV-1 subtype C-infected Zambians, the mean viral load (VL) was lower among 
      B*5703 (P = 0.01) or B*5703-Cw*18 (P < 0.001) haplotype carriers and higher among 
      B*5802 (P = 0.02) or B*5802-Cw*0602 (P = 0.03) carriers. The B*5801-Cw*03 
      haplotype showed an association with low VL (P = 0.05), whereas B*5801 as a whole 
      did not. Rwandans with HIV-1 subtype A infection showed associations of B*5703 
      and B*5802 with slow (P = 0.06) and rapid (P = 0.003) disease progression, 
      respectively. In neither population were B*1516-B*1517 alleles associated with 
      more favorable responses. Overall, B58s alleles, individually or as part of an 
      HLA-B-HLA-C haplotype, appeared to have a distinctive impact on HIV-1 infection 
      among native Africans. As presently defined, B58s alleles cannot be considered 
      uniformly protective against HIV/AIDS in every population.
FAU - Lazaryan, Aleksandr
AU  - Lazaryan A
AD  - Department of Epidemiology, University of Alabama at Birmingham, AL 35294, USA.
FAU - Lobashevsky, Elena
AU  - Lobashevsky E
FAU - Mulenga, Joseph
AU  - Mulenga J
FAU - Karita, Etienne
AU  - Karita E
FAU - Allen, Susan
AU  - Allen S
FAU - Tang, Jianming
AU  - Tang J
FAU - Kaslow, Richard A
AU  - Kaslow RA
LA  - eng
GR  - AI40591/AI/NIAID NIH HHS/United States
GR  - AI41530/AI/NIAID NIH HHS/United States
GR  - AI42454/AI/NIAID NIH HHS/United States
GR  - AI41951/AI/NIAID NIH HHS/United States
GR  - R01 AI041951/AI/NIAID NIH HHS/United States
GR  - U01 AI041530/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Virol
JT  - Journal of virology
JID - 0113724
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
SB  - IM
MH  - Africa/epidemiology
MH  - Black People
MH  - Disease Susceptibility/immunology
MH  - HIV Infections/*epidemiology/*immunology
MH  - HIV-1/*pathogenicity
MH  - HLA-B Antigens/*immunology
MH  - HLA-C Antigens/immunology
MH  - Haplotypes
MH  - Humans
MH  - Rwanda/epidemiology
MH  - Zambia/epidemiology
PMC - PMC1472610
EDAT- 2006/05/30 09:00
MHDA- 2006/08/17 09:00
PMCR- 2006/10/01
CRDT- 2006/05/30 09:00
PHST- 2006/05/30 09:00 [pubmed]
PHST- 2006/08/17 09:00 [medline]
PHST- 2006/05/30 09:00 [entrez]
PHST- 2006/10/01 00:00 [pmc-release]
AID - 80/12/6056 [pii]
AID - 2119-05 [pii]
AID - 10.1128/JVI.02119-05 [doi]
PST - ppublish
SO  - J Virol. 2006 Jun;80(12):6056-60. doi: 10.1128/JVI.02119-05.